papillomavirus infections

Summary

Summary: Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.

Top Publications

  1. ncbi Human papillomavirus and cervical cancer
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Lancet 370:890-907. 2007
  2. pmc The causal relation between human papillomavirus and cervical cancer
    F X Bosch
    Institut Catala d Oncologia, Servei d Epidemiologia i Registre del Cancer, Gran Via Km 2 7 s n 08907 L Hospitalet de Llobregat, 08907 Barcelona, Spain
    J Clin Pathol 55:244-65. 2002
  3. ncbi Papillomaviruses and cancer: from basic studies to clinical application
    Harald zur Hausen
    Deutsches Krebsforschungszentrum, Heidelberg, Germany
    Nat Rev Cancer 2:342-50. 2002
  4. ncbi Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
    Silvia de Sanjose
    IDIBELL, Institut Català d Oncologia Catalan Institute of Oncology, L Hospitalet de Llobregat, Barcelona, Spain
    Lancet Oncol 11:1048-56. 2010
  5. pmc Human papillomavirus and survival of patients with oropharyngeal cancer
    K Kian Ang
    University of Texas M D Anderson Cancer Center, Houston, USA
    N Engl J Med 363:24-35. 2010
  6. pmc Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
    Hans Ulrich Bernard
    Department of Molecular Biology and Biochemistry and Program of Public Health, University of California Irvine, Irvine, CA 92697, USA
    Virology 401:70-9. 2010
  7. ncbi Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer
    Peng Guan
    International Agency for Research on Cancer, Lyon, France
    Int J Cancer 131:2349-59. 2012
  8. ncbi Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
    J Paavonen
    Department of Obstetrics and Gynaecology, University of Helsinki, Helsinki, Finland
    Lancet 374:301-14. 2009
  9. ncbi The global health burden of infection-associated cancers in the year 2002
    Donald Maxwell Parkin
    Clinical Trials Service Unit and Epidemiological Studies Unit, University of Oxford, Headington, UK
    Int J Cancer 118:3030-44. 2006
  10. ncbi Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
    Matti Lehtinen
    University of Tampere, School of Public Health, Tampere, Finland
    Lancet Oncol 13:89-99. 2012

Detail Information

Publications271 found, 100 shown here

  1. ncbi Human papillomavirus and cervical cancer
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Lancet 370:890-907. 2007
    ..If applied wisely, HPV-related technology can minimise the incidence of cervical cancer, and the morbidity and mortality it causes, even in low-resource settings...
  2. pmc The causal relation between human papillomavirus and cervical cancer
    F X Bosch
    Institut Catala d Oncologia, Servei d Epidemiologia i Registre del Cancer, Gran Via Km 2 7 s n 08907 L Hospitalet de Llobregat, 08907 Barcelona, Spain
    J Clin Pathol 55:244-65. 2002
    The causal role of human papillomavirus infections in cervical cancer has been documented beyond reasonable doubt. The association is present in virtually all cervical cancer cases worldwide...
  3. ncbi Papillomaviruses and cancer: from basic studies to clinical application
    Harald zur Hausen
    Deutsches Krebsforschungszentrum, Heidelberg, Germany
    Nat Rev Cancer 2:342-50. 2002
    ..Epidemiological studies have underlined that HPVs are the main aetiological factor for cervical cancer. But how has this knowledge been translated into the clinic to allow the prevention, screening and treatment of cervical cancer?..
  4. ncbi Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
    Silvia de Sanjose
    IDIBELL, Institut Català d Oncologia Catalan Institute of Oncology, L Hospitalet de Llobregat, Barcelona, Spain
    Lancet Oncol 11:1048-56. 2010
    ..We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer...
  5. pmc Human papillomavirus and survival of patients with oropharyngeal cancer
    K Kian Ang
    University of Texas M D Anderson Cancer Center, Houston, USA
    N Engl J Med 363:24-35. 2010
    ..Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown...
  6. pmc Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
    Hans Ulrich Bernard
    Department of Molecular Biology and Biochemistry and Program of Public Health, University of California Irvine, Irvine, CA 92697, USA
    Virology 401:70-9. 2010
    ..We discuss that based on emerging species concepts derived from genome sequences, PV types could be promoted to the taxonomic level of species, but we do not recommend implementing this change at the current time...
  7. ncbi Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer
    Peng Guan
    International Agency for Research on Cancer, Lyon, France
    Int J Cancer 131:2349-59. 2012
    ..HPV16 in particular, but also HPV18 and 45, warrant special attention in HPV-based screening programs...
  8. ncbi Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
    J Paavonen
    Department of Obstetrics and Gynaecology, University of Helsinki, Helsinki, Finland
    Lancet 374:301-14. 2009
    ..We now assess the vaccine efficacy in the final event-driven analysis...
  9. ncbi The global health burden of infection-associated cancers in the year 2002
    Donald Maxwell Parkin
    Clinical Trials Service Unit and Epidemiological Studies Unit, University of Oxford, Headington, UK
    Int J Cancer 118:3030-44. 2006
    ..The attributable fraction at the specific sites varies from 100% of cervix cancers attributable to the papilloma viruses to a tiny proportion (0.4%) of liver cancers (worldwide) caused by liver flukes...
  10. ncbi Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
    Matti Lehtinen
    University of Tampere, School of Public Health, Tampere, Finland
    Lancet Oncol 13:89-99. 2012
    ..We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young Adults)...
  11. ncbi Case-control study of human papillomavirus and oropharyngeal cancer
    Aimee R Kreimer
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
    N Engl J Med 356:1944-56. 2007
    ..Substantial molecular evidence suggests a role for human papillomavirus (HPV) in the pathogenesis of oropharyngeal squamous-cell carcinoma, but epidemiologic data have been inconsistent...
  12. ncbi Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings
    Laia Bruni
    Unit of Infections and Cancer, Cancer Epidemiology Research Program, IDIBELL Institut Català d Oncologia, Barcelona, Spain
    J Infect Dis 202:1789-99. 2010
    ..Baseline information on human papillomavirus (HPV) prevalence and type distribution is highly desirable to evaluate the impact of prophylactic HPV vaccines in the near future...
  13. ncbi Human papillomavirus oncoproteins: pathways to transformation
    Cary A Moody
    Department of MicrobiologyImmunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Nat Rev Cancer 10:550-60. 2010
    ..Understanding how HPV oncoproteins modify these activities provides novel insights into the basic mechanisms of oncogenesis...
  14. ncbi Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
    Cosette M Wheeler
    Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
    Lancet Oncol 13:100-10. 2012
    ....
  15. ncbi Worldwide burden of cervical cancer in 2008
    M Arbyn
    Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
    Ann Oncol 22:2675-86. 2011
    ..Up-to-date and reliable data are needed to assess impact of existing preventive measures and to define priorities for the future...
  16. ncbi Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
    Carole Fakhry
    Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Natl Cancer Inst 100:261-9. 2008
    ....
  17. ncbi HPV-associated head and neck cancer: a virus-related cancer epidemic
    Shanthi Marur
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Lancet Oncol 11:781-9. 2010
    ....
  18. ncbi Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial
    Guglielmo Ronco
    Centre for Cancer Prevention, Turin, Italy
    Lancet Oncol 11:249-57. 2010
    ..We assessed the efficacy of cervical-cancer screening policies that are based on HPV testing...
  19. ncbi Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
    Philip E Castle
    American Society for Clinical Pathology Institute, Washington, DC 20005, USA
    Lancet Oncol 12:880-90. 2011
    ..We did a subanalysis of this population to compare the screening performance of the cobas HPV test versus liquid-based cytology in women aged 25 years and older, and assess management strategies for HPV-positive women...
  20. ncbi Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis
    Silvia de Sanjose
    Servei d Epidemiologia i Registre del Cancer, Institut Catala d Oncologia, Barcelona, Spain
    Lancet Infect Dis 7:453-9. 2007
    ..The HPV types most commonly detected are similar to those most commonly described in pre-neoplastic and cancer cases, although the relative contribution of HPV16 and HPV18 is substantially lower in cytologically normal women...
  21. ncbi Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial
    Dorien C Rijkaart
    Department of Pathology, VU University Medical Centre, Amsterdam, Netherlands
    Lancet Oncol 13:78-88. 2012
    ..The aim of this study was to assess whether HPV DNA testing in the first screen decreases detection of cervical intraepithelial neoplasia (CIN) grade 3 or worse, CIN grade 2 or worse, and cervical cancer in the second screening...
  22. ncbi Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review
    Aimee R Kreimer
    International Agency for Research on Cancer, Lyon, France
    Cancer Epidemiol Biomarkers Prev 14:467-75. 2005
    ..Small sample size and publication bias complicate the assessment of the prevalence of HPV in head and neck sites beyond the oropharynx...
  23. ncbi Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer
    Marc Arbyn
    Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
    Vaccine 30:F88-99. 2012
    ..This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012...
  24. ncbi Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
    Talía Malagón
    Unité de Recherche en Santé des Populations URESP, Centre de Recherche Fonds de la Recherche en Santé du Québec FRSQ du Centre Hospitalier Affilié Universitaire de Québec CHA, Quebec, Canada
    Lancet Infect Dis 12:781-9. 2012
    ....
  25. ncbi Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement
    Virginia A Moyer
    U S Preventive Services Task Force, Rockville, Maryland, USA
    Ann Intern Med 156:880-91, W312. 2012
    ..Update of the 2003 U.S. Preventive Services Task Force (USPSTF) recommendation statement on screening for cervical cancer...
  26. ncbi Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?
    Anders Näsman
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 125:362-6. 2009
    ..In conclusion, the incidence of HPV-positive cancers is still increasing in the County of Stockholm, suggesting an epidemic of a virus-induced carcinoma, with soon practically all tonsillar SCC being HPV positive, as in cervical cancer...
  27. ncbi Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
    Suzanne M Garland
    Microbiology and Infectious Diseases Department, Royal Women s Hospital, and the University of Melbourne, Melbourne, Australia
    N Engl J Med 356:1928-43. 2007
    ..A phase 3 trial was conducted to evaluate the efficacy of a prophylactic quadrivalent vaccine in preventing anogenital diseases associated with human papillomavirus (HPV) types 6, 11, 16, and 18...
  28. ncbi Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication
    Ni Li
    International Agency for Research on Cancer, Lyon, France
    Int J Cancer 128:927-35. 2011
    ..However, estimating the fraction of ICC attributable to different types is increasingly complicated by the detection of multiple HPV infections in ICC...
  29. pmc Improved amplification of genital human papillomaviruses
    P E Gravitt
    Department of Human Genetics, Roche Molecular Systems, Alameda, California, USA
    J Clin Microbiol 38:357-61. 2000
    ..This new primer system will be useful in assessing the natural history of HPV infections, particularly when the analysis requires HPV typing...
  30. pmc Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
    G M Clifford
    International Agency for Research on Cancer, 150, cours Albert Thomas, 69008 Lyon, France
    Br J Cancer 88:63-73. 2003
    ..A majority of ICC was associated with HPV16 or 18 in all regions, but approximately a quarter of all ICC cases were associated with one of 16 other HPV types, their distribution varying by region...
  31. ncbi Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions
    Anna R Giuliano
    Risk Assessment, Detection and Intervention Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Vaccine 26:K17-28. 2008
    ....
  32. ncbi Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women
    Nubia Munoz
    Division of Research and Public Health, National Institute of Cancer, Bogota, Colombia
    J Natl Cancer Inst 102:325-39. 2010
    ....
  33. ncbi Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis
    Dorothy A Machalek
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, NSW, Australia
    Lancet Oncol 13:487-500. 2012
    ..We aimed to assess available data for anal HPV disease that can inform pre-cancer screening programmes...
  34. ncbi The papillomavirus life cycle
    John Doorbar
    Division of Virology, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK
    J Clin Virol 32:S7-15. 2005
    ..As with other DNA tumour viruses, such abortive infections can predispose to cancer...
  35. pmc American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer
    Debbie Saslow
    Cancer Control Science Department, American Cancer Society, Atlanta, GA 30303, USA
    CA Cancer J Clin 62:147-72. 2012
    ....
  36. ncbi The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years
    Darron R Brown
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Infect Dis 199:926-35. 2009
    ..Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated...
  37. ncbi Prevalence of HPV infection among females in the United States
    Eileen F Dunne
    Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    JAMA 297:813-9. 2007
    ..Baseline population prevalence data for HPV infection in the United States before widespread availability of a prophylactic HPV vaccine would be useful...
  38. pmc Human papillomavirus testing in the prevention of cervical cancer
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 103:368-83. 2011
    ..The greatest potential for reduction in cervical cancer rates from HPV screening is in low-resource regions that can implement infrequent rounds of low-cost HPV testing and treatment...
  39. ncbi Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study
    Julia M L Brotherton
    Victorian Cytology Service Registries, Victorian Cytology Service, East Melbourne, Vic, Australia
    Lancet 377:2085-92. 2011
    ..We analysed trends in cervical abnormalities in women in Victoria, Australia, before and after introduction of the vaccination programme...
  40. ncbi Human papillomavirus and Papanicolaou tests to screen for cervical cancer
    Pontus Naucler
    Department of Medical Microbiology, Malmo University Hospital, Lund University, Malmo, Sweden
    N Engl J Med 357:1589-97. 2007
    ....
  41. ncbi High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma
    Lisa Licitra
    Head and Neck Cancer Medical Oncology Unit, Medical Statistics and Biometry, Department of Head and Neck Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Clin Oncol 24:5630-6. 2006
    ..To which extent the viral integration by itself, and/or the associated wild-type (wt) TP53 status, and/or a functional p16 contribute to prognosis is unclear...
  42. ncbi Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study
    Rolando Herrero
    International Agency for Research on Cancer, Lyon, France rherrero amnet co cr
    J Natl Cancer Inst 95:1772-83. 2003
    ..To investigate these associations, we conducted a multicenter case-control study of cancer of the oral cavity and oropharynx in nine countries...
  43. ncbi Against which human papillomavirus types shall we vaccinate and screen? The international perspective
    Nubia Munoz
    International Agency for Research on Cancer, Lyon, France
    Int J Cancer 111:278-85. 2004
    ..The impact of modifying the number of types in the screening cocktail tests would be small and probably irrelevant for screening programs...
  44. pmc Bead-based multiplex genotyping of human papillomaviruses
    Markus Schmitt
    Research Program Infection and Cancer, German Cancer Research Center DKFZ, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany
    J Clin Microbiol 44:504-12. 2006
    ..922) but also indicated a higher sensitivity of MPG. In conclusion, MPG appears to be highly suitable for large-scale epidemiological studies and vaccination trials as well as for routine diagnostic purposes...
  45. ncbi Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial
    Simon R M Dobson
    Department of Pediatrics, University of British Columbia, Vancouver, Canada
    JAMA 309:1793-802. 2013
    ..Global use of human papillomavirus (HPV) vaccines to prevent cervical cancer is impeded by cost. A 2-dose schedule for girls may be possible...
  46. pmc A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection
    Stéphanie Longet
    Department of Urology, CHUV, c o IMUL, Bugnon 48, 1011 Lausanne, Switzerland
    J Virol 85:13253-9. 2011
    ..The results clearly demonstrate that, remarkably, the in vivo assay is substantially more sensitive than in vitro PsV neutralization and thus may be better suited for studies to establish correlates of protection...
  47. ncbi HPV vaccine against anal HPV infection and anal intraepithelial neoplasia
    Joel M Palefsky
    Department of Medicine, University of California at San Francisco, Box 0654, San Francisco, CA 94143, USA
    N Engl J Med 365:1576-85. 2011
    ..We studied the safety and efficacy of quadrivalent HPV vaccine (qHPV) against anal intraepithelial neoplasia associated with HPV-6, 11, 16, or 18 infection in men who have sex with men...
  48. pmc Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males
    Anna R Giuliano
    Risk Assessment, Detection, and Intervention Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    N Engl J Med 364:401-11. 2011
    ..We report on the safety of a quadrivalent vaccine (active against HPV types 6, 11, 16, and 18) and on its efficacy in preventing the development of external genital lesions and anogenital HPV infection in boys and men...
  49. ncbi HPV screening for cervical cancer in rural India
    Rengaswamy Sankaranarayanan
    International Agency for Research on Cancer, Lyon, France
    N Engl J Med 360:1385-94. 2009
    ....
  50. ncbi Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries
    Jack Cuzick
    Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, London, United Kingdom
    Vaccine 26:K29-41. 2008
    ..These psychosocial aspects and the need for more information and educational programmes about HPV are also discussed in this article...
  51. ncbi Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students
    Rachel L Winer
    Department of Epidemiology, University of Washington, Seattle, WA 98103, USA
    Am J Epidemiol 157:218-26. 2003
    ..The data show that the incidence of HPV associated with acquisition of a new sex partner is high and that nonpenetrative sexual contact is a plausible route of transmission in virgins...
  52. ncbi Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial
    Nubia Munoz
    National Institute of Cancer, Bogota, Colombia
    Lancet 373:1949-57. 2009
    ..We tested the safety, immunogenicity, and efficacy of the quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like-particle vaccine in women aged 24-45 years...
  53. ncbi Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
    Gemma G Kenter
    Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands
    N Engl J Med 361:1838-47. 2009
    ..Spontaneous regression occurs in less than 1.5% of patients, and the rate of recurrence after treatment is high...
  54. ncbi Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data
    Basil Donovan
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
    Lancet Infect Dis 11:39-44. 2011
    ..We established a national surveillance network in Australia and aimed to identify trends in diagnoses of genital warts in 2004-09...
  55. ncbi Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review
    Karly S Louie
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
    Trop Med Int Health 14:1287-302. 2009
    ..To identify the gaps of knowledge and highlight the challenges and opportunities for controlling cervical cancer in sub-Saharan Africa (SSA)...
  56. pmc Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years
    Mark H Einstein
    Department of Obstetrics and Gynecology and Women s Health, Division of Gynecologic Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
    Hum Vaccin 7:1343-58. 2011
    ..Both vaccines were generally well tolerated. Although an immunological correlate of protection has not been defined, differences in the magnitude of immune response between vaccines may represent determinants of duration of protection...
  57. pmc HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study
    Murat Gok
    Department of Pathology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, Netherlands
    BMJ 340:c1040. 2010
    ..To determine whether offering self sampling of cervicovaginal material for high risk human papillomavirus (HPV) testing is an effective screening method for women who do not attend regular cervical screening programmes...
  58. pmc Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years
    Mark H Einstein
    Department of Obstetrics and Gynecology and Women s Health, Division of Gynecologic Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
    Hum Vaccin 7:1359-73. 2011
    ..Considering the differences in cross-protective efficacy between the two vaccines, the results might provide insights into the underlying mechanism(s) of protection...
  59. ncbi Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States
    Anil K Chaturvedi
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 26:612-9. 2008
    ....
  60. ncbi Molecular biology of human papillomavirus infection and cervical cancer
    John Doorbar
    Division of Virology, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK
    Clin Sci (Lond) 110:525-41. 2006
    ..In most individuals, immune regression eventually leads to clearance of the virus, or to its maintenance in a latent or asymptomatic state in the basal cells...
  61. ncbi Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis
    H zur Hausen
    Deutsches Krebsforschungszentrum, Heidelberg, Germany
    J Natl Cancer Inst 92:690-8. 2000
    ..Modifications in host-cell genes, most likely engaged in the control of HPV gene expression in proliferating cells, emerge as important events in HPV-mediated carcinogenesis...
  62. ncbi HPV vaccine acceptability in Ghana, West Africa
    Maame Aba Coleman
    Baylor College of Medicine, Department of Obstetrics and Gynecology, Houston, TX 77030, USA
    Vaccine 29:3945-50. 2011
    ..Cervical cancer is a leading cause of cancer-related mortality among women in Ghana. As of this writing no data are available concerning knowledge, attitudes and acceptability of human papillomavirus (HPV) vaccination by women in Ghana...
  63. ncbi Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia
    J T Keating
    Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Surg Pathol 25:884-91. 2001
    ....
  64. pmc Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia
    Kate Cuschieri
    Specialist Virology Centre, Royal Infirmary of Edinburgh, United Kingdom
    Cancer Epidemiol Biomarkers Prev 17:2536-45. 2008
    ..Currently, there is promising data indicating that HPV mRNA and p16 might play an important role in future cervical cancer screening scenarios. Still, large randomized studies are necessary to confirm the preliminary data...
  65. pmc Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)
    Farshid Dayyani
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Head Neck Oncol 2:15. 2010
    ..HPV is important in a subset of HNSCC. Our meta-analysis determined the clinical characteristics of HPV-related HNSCC...
  66. pmc End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
    X Castellsague
    Unit of Infections and Cancer, Cancer Epidemiology Research Program, IDIBELL, Institut Català d Oncologia ICO, CIBER ESP, L Hospitalet de Llobregat, Catalonia 08907, Spain
    Br J Cancer 105:28-37. 2011
    ..In this report, we present end-of-study efficacy, safety, and immunogenicity data with a median follow-up time of 4.0 years...
  67. ncbi Prevalence of oral HPV infection in the United States, 2009-2010
    Maura L Gillison
    Viral Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    JAMA 307:693-703. 2012
    ..However, little is known about the epidemiology of oral HPV infection...
  68. ncbi The natural history of cervical HPV infection: unresolved issues
    Ciaran B J Woodman
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Nat Rev Cancer 7:11-22. 2007
    ..We discuss areas of uncertainty, and their possible effect on disease prevention strategies...
  69. ncbi Carcinogenicity of human papillomaviruses
    Vincent Cogliano
    Lancet Oncol 6:204. 2005
  70. ncbi Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
    A Szarewski
    Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
    Int J Cancer 131:106-16. 2012
    ..The vaccine did not impact the outcome of HPV-16/18 infections present at the time of vaccination. Vaccination was generally well tolerated regardless of the woman's HPV-16/18 DNA or serological status at entry...
  71. ncbi Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe
    Wiebren A Tjalma
    Department of Gynecology and Gynecologic Oncology, University Hospital Antwerpen, University of Antwerp, Antwerpen, Belgium
    Int J Cancer 132:854-67. 2013
    ..These findings support the need for primary prevention of HPV16/18/45-related cervical lesions...
  72. pmc Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis
    Beibei Lu
    Risk Assessment, Detection and Intervention Program, H, Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    BMC Infect Dis 11:13. 2011
    ..We conducted a systematic review and meta-analysis to assess efficacy and safety of prophylactic HPV vaccines against cervical cancer precursor events in women...
  73. ncbi Age-specific prevalence of infection with human papillomavirus in females: a global review
    Jennifer S Smith
    Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    J Adolesc Health 43:S5-25, S25.e1-41. 2008
    ..Global data on age-specific prevalence of human papillomavirus (HPV) infection overall, and for high-risk HPV types 16 and 18, are essential for the future implementation of HPV prophylactic vaccines for cervical cancer prevention...
  74. ncbi Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation
    Rebecca Howell-Jones
    HIV STI Department, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 30:3867-75. 2012
    ..Here we describe type-specific HPV prevalence in three samples of the young female population in England, prior to the beginning of mass immunisation in 2008...
  75. pmc Anal HPV infection in HIV-positive men who have sex with men from China
    Lei Gao
    State Key Laboratory for Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    PLoS ONE 5:e15256. 2010
    ..However, HIV and anal HPV co-infection among MSM has not been addressed in China...
  76. ncbi Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies
    Joseph E Tota
    McGill University, Division of Cancer Epidemiology, 546 Pine Avenue West, Montreal, QC, Canada
    Prev Med 53:S12-21. 2011
    ..Introduction of well organized vaccination and screening programs should be a priority for all countries. Increased support from donors is needed to support this cause...
  77. ncbi The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice
    Michelle J Khan
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Rm 7074, Rockville, MD 20852, USA
    J Natl Cancer Inst 97:1072-9. 2005
    ....
  78. pmc Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries
    D Scott LaMontagne
    PATH, PO Box 900922, Seattle, WA, 98109, United States of America
    Bull World Health Organ 89:821-830B. 2011
    ..To assess human papillomavirus (HPV) vaccination coverage after demonstration projects conducted in India, Peru, Uganda and Viet Nam by PATH and national governments and to explore the reasons for vaccine acceptance or refusal...
  79. ncbi Chapter 2: The burden of HPV-related cancers
    D Maxwell Parkin
    Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building, University of Oxford, Old Road Campus, Oxford, UK
    Vaccine 24:S3/11-25. 2006
    ..We also present trends in incidence and mortality of these cancers in the past, and consider their likely future evolution...
  80. ncbi Current concepts on human papillomavirus infections in children
    Stina Syrjanen
    Department of Oral Pathology and Oral Radiology, Institute of Dentistry and MediCity Research Laboratory, University of Turku, Finland
    APMIS 118:494-509. 2010
    ..Early in life, infections by the high-risk HPV genotypes may also remain persistent for a considerable period, and should be of considerable importance for HPV vaccination strategies...
  81. pmc Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial
    Joakim Dillner
    Depatment of Laboratory Medicine, Lund University, Malmo, Sweden
    BMJ 341:c3493. 2010
    ..To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts (condyloma acuminata)...
  82. ncbi Predictors of HPV vaccine acceptability: a theory-informed, systematic review
    Noel T Brewer
    Department of Health Behavior and Health Education, School of Public Health, University of North Carolina, 306 Rosenau Hall CB 7440, Chapel Hill, NC 27516, USA
    Prev Med 45:107-14. 2007
    ....
  83. pmc Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study
    Joakim Dillner
    Lund University, Medical Microbiology, University Hospital MAS, 205 02 Malmo, Sweden
    BMJ 337:a1754. 2008
    ..To obtain large scale and generalisable data on the long term predictive value of cytology and human papillomavirus (HPV) testing for development of cervical intraepithelial neoplasia grade 3 or cancer (CIN3+)...
  84. ncbi Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia
    F Xavier Bosch
    Cancer Epidemiology Research Program CERP, Institut Català d Oncologia Catalan Institute of Oncology ICO, L Hospitalet de Llobregat Barcelona, Spain
    Vaccine 26:K1-16. 2008
    ....
  85. ncbi Prevalence of HPV infection among men: A systematic review of the literature
    Eileen F Dunne
    Division of STD Prevention, US Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 194:1044-57. 2006
    ..2 million persons are newly infected every year in the United States. There are limited data on HPV infection in heterosexual men...
  86. pmc Clinical validation of the cobas 4800 HPV test for cervical screening purposes
    D A M Heideman
    Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    J Clin Microbiol 49:3983-5. 2011
    ..Accordingly, the cobas 4800 HPV test can be considered clinically validated for cervical screening...
  87. pmc The known unknowns of HPV natural history
    Patti E Gravitt
    Perdana University Graduate School of Medicine, Serdang, Malaysia
    J Clin Invest 121:4593-9. 2011
    ..Here, we examine the epidemiological and biological understanding of the natural history of HPV infection, with an eye toward using these studies to guide the implementation of cervical cancer prevention strategies...
  88. pmc Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model
    Mark Jit
    Health Protection Agency, London NW9 6BT, UK
    BMJ 343:d5775. 2011
    ....
  89. pmc Economic evaluation of human papillomavirus vaccination in the United Kingdom
    Mark Jit
    Modelling and Economics Unit, Centre for Infections, Health Protection Agency, London NW9 6BT
    BMJ 337:a769. 2008
    ..To assess the cost effectiveness of routine vaccination of 12 year old schoolgirls against human papillomavirus infection in the United Kingdom...
  90. pmc Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England
    R Howell-Jones
    HIV and STI Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Br J Cancer 103:209-16. 2010
    ....
  91. ncbi Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003
    A Blythe Ryerson
    Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA
    Cancer 113:2901-9. 2008
    ..The objective of the current study was to describe the incidence rates of oropharyngeal and oral cavity cancers in the US with a focus on anatomic sites potentially associated with HPV infection...
  92. pmc Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States
    Cosette M Wheeler
    House of Prevention Epidemiology, Department of Molecular Genetics and Microbiology, School of Medicine, University of New Mexico Health Sciences Center, 1816 Sigma Chi Rd Bldg 191, Albuquerque, NM 87131, USA
    J Natl Cancer Inst 101:475-87. 2009
    ..Such studies are needed to predict how HPV vaccination and HPV-based screening will influence cervical cancer prevention...
  93. ncbi Human papillomavirus prevalence and type distribution in penile carcinoma
    C Miralles-Guri
    Unit of Infections and Cancer UNIC, Cancer Epidemiology Research Program, Institut Catala d Oncologia, IDIBELL, L Hospitalet de Ll, Barcelona, Spain
    J Clin Pathol 62:870-8. 2009
    ..HPV prevalence in penile tumours is reported to be associated to a variety of morphological changes. Its determination will provide a better estimate for HPV related cancer burden and its preventable fraction...
  94. ncbi Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV)
    Francois Aubin
    Service de Dermatologie, Hospital University Saint Jacques, Besancon, France
    Clin Infect Dis 47:610-5. 2008
    ....
  95. pmc Papillomavirus E6 proteins
    Heather L Howie
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Virology 384:324-34. 2009
    ....
  96. pmc HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    Vaccine 29:2011-4. 2011
    ..001; HPV45, p<0.001) and correlated with HPV16/18 neutralizing titers, respectively. These findings raise the possibility that cross-neutralizing antibodies are effectors of cross-protection observed for the HPV16/18 vaccine...
  97. pmc In vivo mechanisms of vaccine-induced protection against HPV infection
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute National Institutes of Health, Bethesda, MD 20892, USA
    Cell Host Microbe 8:260-70. 2010
    ..Regardless of the concentration, L2 vaccine-induced antibodies allow BM association but prevent association with the cell surface. Thus, we have revealed distinct mechanisms of vaccine-induced inhibition of virus infection in vivo...
  98. pmc Risk of human papillomavirus-associated cancers among persons with AIDS
    Anil K Chaturvedi
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7072, Rockville, MD 20852, USA
    J Natl Cancer Inst 101:1120-30. 2009
    ....
  99. pmc Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda
    David Serwadda
    School of Public Health, Makerere University, Kampala, Uganda
    J Infect Dis 201:1463-9. 2010
    ..00; 95% CI 0.65-1.53) or clearance of HR-HPV infections (RR, 1.09; 95% CI 0.94-1.27). Circumcision of HIV-positive men reduced the prevalence and incidence of multiple HR-HPV infections...
  100. pmc Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005-2008)
    Shona Hilton
    Medical Research Council, Social and Public Health Sciences Unit, 4 Lilybank Gardens, Glasgow, United Kingdom
    Soc Sci Med 70:942-50. 2010
    ..Secondly, the focus on prevalence rates of HPV infection among women and on women's sexual behaviours, in relation to HPV vaccination 'encouraging' promiscuity, is an unhelpful aspect of media coverage...
  101. pmc Could human papillomaviruses be spread through blood?
    Sohrab Bodaghi
    HIV and AIDS Malignancy Branch, Center for Cancer Research, NCI NIH, 10 Center Dr, Rm 10 S255, MSC 1868, Bethesda, MD 20892 1868, USA
    J Clin Microbiol 43:5428-34. 2005
    ..Our data suggest that PBMCs may be HPV carriers and might spread the virus through blood...

Research Grants63

  1. Identification and Preclinical Testing of Microbicides
    Paul Lambert; Fiscal Year: 2007
    ..This breakthrough provides sufficient amounts of papillomavirus to allow one to screen for microbicides as well as to develop the RhPV1 -based nonhuman primate model for anogenital papillomavirus infections.
  2. A topical treatment for genital papillomavirus infections
    Richard Schlegel; Fiscal Year: 2007
    ..Schiller, we will evaluate carrageenan's ability to inhibit vaginal papillomavirus infections. The second compound is dihydroartemisinin (derived from the Chinese herb, Artemisia annua)...
  3. Papillomavirus E2 Functions: Cellular Regulation and Effectors
    Peter M Howley; Fiscal Year: 2013
    ..Such compounds would be useful tools for further studies of HPV-host cell interactions and could serve as potential leads for modeling novel antivirals to treat papillomavirus infections.
  4. Development of a Primate Model for Genital Papillomavirus Infection
    Robert D Burk; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Genital papillomavirus infections are the most common sexually transmitted infections (STIs) among women in the United States and throughout the world...
  5. Human Papillomavirus Infection and Expression of COX-2
    Bettie M Steinberg; Fiscal Year: 2013
    ..Elevated levels of COX-2 are also seen in genital papillomavirus infections, and early clinical studies have found that inhibition of COX-2 significantly improves both RRP and ..
  6. Papillomavirus Host Interation
    Neil D Christensen; Fiscal Year: 2013
    ..HPV infections;(ii) which viral epitopes produce the most potent protective and therapeutic immunity to papillomavirus infections and associated cancer;(iii) what role CD8+ T-cells play in control and clearance of HPV infections, and (..
  7. Intra-molecular interactions control papillomavirus E1 function.
    Arne Stenlund; Fiscal Year: 2012
    ..recently developed vaccines promise to reduce the prevalence of this disease, for the foreseeable future papillomavirus infections will still present a formidable problem due to the large number of already infected individuals...
  8. Emerging Papillomaviruses in Immunosuppressed Dogs
    Richard Schlegel; Fiscal Year: 2011
    ..Emerging papillomavirus infections and the tumors that they induce are increasingly complicating the study of immunosuppressed dogs...
  9. Emerging Papillomaviruses in Immunosuppressed Dogs
    Richard Schlegel; Fiscal Year: 2013
    ..Emerging papillomavirus infections and the tumors that they induce are increasingly complicating the study of immunosuppressed dogs...
  10. Identification and Preclinical Testing of Microbicides
    Paul F Lambert; Fiscal Year: 2010
    ..This breakthrough provides sufficient amounts of papillomavirus to allow one to screen for microbicides as well as to develop the RhPV1 -based nonhuman primate model for anogenital papillomavirus infections.
  11. VIVO OF PAPILLOMAVIRUS TRANSFORMING GENES
    Janet Brandsma; Fiscal Year: 1992
    ..that immune reactions to both virus and tumor associated antigens develop in individuals with papillomavirus infections. Investigations of HPV induced disease have been hampered by of the lack of a good animal model...
  12. MID AMERICA ADOLESCENT STD COOPERATIVE RESEARCH CENTER
    Donald Orr; Fiscal Year: 2003
    ..The fourth project will explore the pathogenesis of human papillomavirus infections with emphasis on the controlling susceptibility to infection...
  13. PAPILLOMAVIRUS TRANSFORMATION OF HUMAN KERATINOCYTES
    Lucia Pirisi Creek; Fiscal Year: 1993
    ..interactions with its host cell will lead to more rational approaches for the diagnosis and therapy of papillomavirus infections of the genital tract, and for a more precise assessment of the risk connected with infection by specific ..
  14. Papillomavirus Inhibitors for AIDS-related Malignancies
    Elliot Androphy; Fiscal Year: 2005
    ..HIV-infected individuals are particularly susceptible to developing papillomavirus infections and associated malignancies. Papillomavirus infection is also a major problem in the general population...
  15. PAPILLOMAVIRUS ANIMAL MODEL/THERAPY EVALUATION
    JOHN KERGDER; Fiscal Year: 1992
    b>Papillomavirus infections are responsible for several clinically important diseases...
  16. THERAPEUTIC STRATEGIES FOR PAPILLOMAVIRUS INFECTIONS
    Neil Christensen; Fiscal Year: 2000
    ..animal model systems to evaluate the efficiency of experimental antiviral substances to control papillomavirus infections. The second is to integrate in vitro systems to permit the mechanistic analysis of experimental ..
  17. THERAPEUTIC STRATEGIES FOR PAPILLOMAVIRUS INFECTIONS
    William Bonnez; Fiscal Year: 2000
    ..animal model systems to evaluate the efficiency of experimental antiviral substances to control papillomavirus infections. The second is to integrate in vitro systems to permit the mechanistic analysis of experimental ..
  18. COGNITIVE AND EMOTIONAL RESPONSES TO AN HPV DIAGNOSIS IN MEN
    Ellen M Daley; Fiscal Year: 2010
    ..These data will assist in the planning, implementation, and evaluation of interventions to reduce HPV infection in both sexes. ..
  19. NATURAL HISTORY OF HPV--INFECTION TO NEOPLASIA
    Anna Barbara Moscicki; Fiscal Year: 2004
    ..The understanding of both local and systemic immune responses to initial and subsequent HPV infections may be key in vaccine or therapeutic developments. ..
  20. Natural History of CIN2 in Adolescents
    Anna Barbara Moscicki; Fiscal Year: 2007
    ..S. and specifically assess how best to modify cytology-based screening, utilize HPV diagnostics, and tailor aoDrooriate follow-uo strategies for adolescents and vouna women diaanosed with CIN 2 ..
  21. Effect of Male Circumcision on Penile HPV Infection
    JENNIFER SUSAN SMITH; Fiscal Year: 2010
    ..If male circumcision is found to be effective and safe in reducing HPV infection or penile lesions in men, it could in turn reduce HPV prevalence and associated cervical neoplasia in women. ..
  22. EPIDEMIOLOGY OF HPV16/18 VARIANTS IN CERVICAL NEOPLASIA
    Long Fu Xi; Fiscal Year: 2003
    ..The proposed study is likely to make important contributions to our understanding of the role of HPV 16 and 18 variants in the pathogenesis of cervical cancer. ..
  23. DNA Methylation as a Risk Factor for Cervical Neoplasia
    Long Fu Xi; Fiscal Year: 2009
    ..Data from the proposed study will not only shed light on our understanding of the role of CpG methylation in development of cervical neoplasia but also help to better design future cervical cancer control programs. ..
  24. HPV Outcomes: Prevention Epidemiology and Surveillance (HOPES)
    Cosette Marie Wheeler; Fiscal Year: 2010
    ..Image-based diagnostic standards will be critical to future population evaluations. ..
  25. Prognostic Significance of DNA and Histone Methylation
    Chandrika Piyathilake; Fiscal Year: 2007
    ..Investigator talent, equipment, facilities and access to study subjects at UAB are ideal for conducting this study. ..
  26. Partners in Action: A UM/ Little Haiti Collaborative United Against Breast Cancer
    Erin Kobetz; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  27. HIV Testing and Women's Attitudes on HIV Vaccine Trials
    Gregory D Zimet; Fiscal Year: 2010
    ..abstract_text> ..
  28. HPV Clearance by Folic Acid Supplementation
    Chandrika J Piyathilake; Fiscal Year: 2010
    ..Because this study will be conducted among women positive for HPV 16, the most prevalent and powerful causative agent of CC, the public health significance of this study could be enormous and will complement HPV vaccine studies. ..
  29. Effect of Oxidant Load on HPV Persistence and CIN (SIL)
    Anna Giuliano; Fiscal Year: 2008
    ..abstract_text> ..
  30. Human Papillovirus Testing in Adolescents
    Jessica Kahn; Fiscal Year: 2006
    ..Aim 5 To determine the cumulative prevalence and rates of persistence and regression of HPV infection, and correlation of HPV test results with cervicaI cytology, in the above sample of urban adolescent girls. ..
  31. Prognostic Significance of Altered DNA Methylation
    Chandrika Piyathilake; Fiscal Year: 2002
    ..A newly developed and tested immunohistochemical technique, which measures the degree of global methylation in intact and specific types of cells, will be used to evaluate global DNA methylation in the proposed study. ..
  32. Interventions to Increase HBV Vaccination in STD Clinics
    Gregory Zimet; Fiscal Year: 2006
    ..The relationships of the interventions, socio-demographics, attitudes and behaviors to the outcome measures will be assessed with multiple logistic regression (MLR) and path analysis via structural equation modeling. ..
  33. Control of Human Papillomavirus-16 Transcription
    Hans Ulrich Bernard; Fiscal Year: 2006
    ....
  34. Effects of Folate Fortification on Cancer Prevention an*
    Chandrika Piyathilake; Fiscal Year: 2005
    ....
  35. Cervical Cancer Screening in Lesbians
    J Tracy; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  36. Potential for HIV transmission in relationships of drug-using women in Russia
    Linda Niccolai; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  37. DIET AND DURATION OF CERVICAL HPV INFECTION
    MARC GOODMAN; Fiscal Year: 2009
    ....
  38. MOLECULAR EPIDEMIOLOGY OF PERSISTENT HPV INFECTION
    Eduardo Franco; Fiscal Year: 2003
    ..abstract_text> ..
  39. African American Multi-construct Survey of Cultural Attitudes Relevant to Cancer
    VETTA LYNN SANDERS THOMPSON; Fiscal Year: 2010
    ..This information will be used in developing health education and promotion materials and interventions that more effectively target the African American community. ..
  40. Oral HPV Infection in HIV-Infected Men and Women
    Maura Gillison; Fiscal Year: 2008
    ..This proposal has the potential to yield information important for future efforts at primary prevention and early detection of HPV-HNSCC. ..
  41. Screening for STDs using home sampling in Estonia
    Anneli Uuskula; Fiscal Year: 2007
    ..This information will allow us to identify STD infected individuals, and to develop selective screening criteria to be used in general population studies and screening programs in Estonia. ..
  42. Effect of hormonal contraception on bone mineral density
    Abbey Berenson; Fiscal Year: 2005
    ..Ultimately, this study will determine which women, if any, are placed at increased risk of osteopenia or osteoporosis as a result of using these hormonal contraceptives during their reproductive years. ..
  43. A Phase I/II Trial of a Therapeutic HPV Vaccine
    Cornelia Trimble; Fiscal Year: 2004
    ....
  44. THERAPEUTIC VACCINES FOR HPV DISEASES
    Cornelia Trimble; Fiscal Year: 2005
    ..These facilities will be used to develop Dr. Trimble's ability to design and execute clinical trials evaluating preneoplastic HPV-associated lesions of the female lower genital tract. ..
  45. Therapeutic DNA-MVA prime boost vaccination for HPV disease
    Cornelia Trimble; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  46. Mutational load in buccal cells from lung cancer patients and controls
    Robbert Slebos; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  47. Molecular Interactions in B cell Development
    JAMES BALEJA; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  48. Molecular Interactions in Signaling and Vesicle Sorting
    JAMES BALEJA; Fiscal Year: 2007
    ..These investigations on the EH domain:NPF interaction are also expected to advance the application of NMR in understanding molecular recognition. ..
  49. STDS, FERTILITY, MARRIAGE AND DEMOGRAPHIC PROJECTION
    Ronald Gray; Fiscal Year: 2002
    ..In collaboration with the U.S. Bureau of Census, data from the proposed study will be used to revise demographic projections of the effects of HIV on population growth, composition and AIDS orphanhood. ..
  50. COORDINATED CONTROL OF HPV TRANSCRIPTION AND REPLICATION
    Kenneth Alexander; Fiscal Year: 2002
    ..The data gained from this study will be used to create a dynamic model of HPV transcription and replication control that will be broadly applicable to transcription and replication control in DNA viruses. ..
  51. CYTOTOXIC T LYMPHOCYTE RESPONSE TO HPV 16
    Mayumi Nakagawa; Fiscal Year: 2002
    ....
  52. BENIGN BREAST DISEASE--MOLECULAR DIFFERENTIATION OF RISK
    Maria Worsham; Fiscal Year: 2001
    ....
  53. Rapid Strip Test for Cervical Cancer via HPV-E6 Detection
    Johannes Schweizer; Fiscal Year: 2007
    ..In a Phase II SBIR, we would test prototype efficacy on a large number of clinical samples and optimize, if necessary, for FDA submission. [unreadable] [unreadable]..
  54. VSV-based Therapeutic Papilloma Vaccine
    Janet Brandsma; Fiscal Year: 2007
    ..The data provided by this investigation are likely to aid in the development a highly effective HPV vaccine to protect women against cervical cancer. ..
  55. Testing a video to improve provider-patient interaction
    Deborah Helitzer; Fiscal Year: 2006
    ..This research addresses the priorities of announcement PAR-04-117 "Understanding and Promoting Health Literacy." ..
  56. Surveillance Strategies Following Treatment for CIN
    Joy Melnikow; Fiscal Year: 2007
    ..Alternative strategies for post-treatment surveillance will be evaluated. [unreadable] [unreadable] [unreadable]..
  57. DEPRESSION AND PRODUCTIVE WORK ACTIVITY
    Debra Lerner; Fiscal Year: 2003
    ..Study results will contribute to the design of disability prevention and productivity improvement programs and policies. ..
  58. Hepatitis B ESL Education for Chinese
    Victoria Taylor; Fiscal Year: 2009
    ..Our primary outcome will be HBV serologic testing. Knowledge about key hepatitis B facts will be examined as a secondary outcome. ..
  59. Use of Serum HPV16 DNA as a Marker for Oropharyngeal Cancer Recurrence
    Erich Sturgis; Fiscal Year: 2008
    ..abstract_text> ..
  60. AIDS Diarrhea and Antiretroviral Drug Absorption
    Daniel Fitzgerald; Fiscal Year: 2006
    ..abstract_text> ..
  61. WELLNESS CIRCLES--AN AMERICAN INDIAN APPROACH
    Felicia Hodge; Fiscal Year: 2002
    ..Phase III will consist of data analysis and evaluation. The leadership of this team includes American Indian investigators experienced in cancer control research and knowledgeable in the provision of culturally sensitive care. ..
  62. REPEAT MAMMOGRAPHY AMONG LOW INCOME AND MINORITY WOMEN
    Maria Fernandez; Fiscal Year: 2003
    ..g. stage of mammography adoption, self-efficacy, attitudes toward mammography, and perceived susceptibility to breast cancer). ..